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Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the most common cardiac
disease in cats. However, most cats are not diagnosed until they develop congestive
heart failure, arterial thromboembolism (ATE), or sudden cardiac death. Thus, an
affordable screening test for early detection of HCM is desirable.
Hypothesis/Objectives: Evaluation of a sensitive cardiac troponin I (cTnI) assay
as a screening test for HCM in cats and determination of a cutoff for its early
detection.
Animals: One hundred sixty-six client-owned cats (male, n = 97) of various breeds
were evaluated and classified using echocardiography as being healthy (n = 87),
equivocal (n = 15), or having HCM (mild, n = 16; moderate, n = 10; severe, n = 34)
or ATE (n = 4).
Methods: All cats were prospectively evaluated by echocardiography, and serum cTnI
concentration was determined using the currently most sensitive assay (Siemens
ADVIA Centaur TnI-Ultra).
Results: The median cTnI concentration was significantly different between study
groups (P < .000001). A cutoff of 0.06 ng/mL provided good discrimination
between healthy cats and cats with HCM (sensitivity, 91.7%; specificity, 95.4%;
area under the curve [AUC], 0.95; 95% confidence interval [CI], 0.899-0.978).
Even for asymptomatic cats with HCM, sensitivity and specificity for a cutoff of
>0.06 ng/mL remained high at 87.8% and 95.4%, respectively (AUC, 0.93; 95% CI,
0.864-0.964).
Conclusions and clinical importance: Cardiac troponin I can be used as a sensitive
and specific screening test for the diagnosis of HCM in otherwise healthy cats (cut-
off, >0.06 ng/mL). However, echocardiography is needed to confirm the diagnosis.
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1 | INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common cardiac
disease in cats.1–3 It is defined as hypertrophy of the left ventricle4,5
without identifiable underlying cause, such as systemic hypertension,6
hyperthyroidism,7,8 or, less commonly, congenital aortic stenosis,9
multicentric lymphoma,10 acromegaly,11 or pseudohypertrophy as a
consequence of dehydration.12 Frequently, cats are not diagnosed
until they are presented with congestive heart failure (CHF), arterial
thromboembolism (ATE), or sudden cardiac death.13,14 According to a
previous study,3 14.7% of 780 apparently healthy cats had echocar-
diographic evidence of HCM. Furthermore, in another study, 30.5% of
cats with preclinical HCM or hypertrophic obstructive cardiomyopa-
thy developed CHF, ATE, or both, and 27.9% died for cardiovascular
reasons,15 thus emphasizing the need for a reliable screening test.
Currently, echocardiographic examination remains the gold standard
for the diagnosis of HCM,16 but it requires specialized equipment and
a trained cardiologist. Many owners may be reluctant to take their
apparently healthy cat to a specialist for such a costly examination.17
Therefore, an easily available and affordable screening test would
be helpful to identify cats that would benefit from more extensive
diagnostic evaluation. During the last decade, biomarkers such as
N-terminal pro-B type natriuretic peptide (NT-proBNP) and cardiac
troponin I (cTnI) have been studied extensively in the assessment of
cardiac diseases in cats.17–25 For NT-proBNP, a cutoff already has
been proposed for differentiating normal cats from cats only mildly
affected with HCM.21,22 Regarding cTnI, it has already been shown
that cats with HCM have significantly higher serum cTnI concentra-
tions than do healthy control cats, and that a correlation exists between
left ventricular free wall thickness and the serum concentration of
cTnI.18,19,26 Some investigators state that cTnI only can be used to dif-
ferentiate cats with moderate-to-severe HCM from healthy cats, thus
rendering it less useful as a screening test.27 Recently a cutoff of
0.163 ng/mL has been proposed to distinguish healthy cats from cats
with HCM without left atrial dilatation.26 However, because of a sensi-
tivity of 62%, its value as a screening test remains unknown.
Our aim was to evaluate the utility of a sensitive cTnI assay as a
screening test for cats with HCM and to determine the appropriate
cutoff to identify cats that would benefit from a more extensive
echocardiographic evaluation. Second, we aimed to identify factors
that might influence the cTnI concentration in these cats as well as
to detect correlations between cTnI concentration and certain echo-
cardiographic variables.
2 | MATERIALS AND METHODS
2.1 | Animals
All cats were client-owned and evaluated prospectively. Informed
owner consent was obtained before participation in the study and
all examinations followed German guidelines for animal care and
use. Cats were excluded if they had a potential reason for having
secondary left ventricular hypertrophy (eg, systemic hypertension
and hyperthyroidism), other cardiac disease, or kidney disease.
Healthy control cats had to have left ventricular wall thicknesses
<5.0 mm and left-atrial-to-aorta ratio (LA/Ao) ≤1.5. Cats with left
ventricular wall thicknesses between 5.0 and 6.0 mm or moderate
papillary muscle hypertrophy were classified as equivocal.28 Hypertro-
phic cardiomyopathy was defined as a generalized or focal end-
diastolic left ventricular wall thickness ≥6.0 mm, severe hypertrophy
of the papillary muscles, or both.28,29 Further classification of cats
with HCM into mild, moderate, and severe was done as previously
reported.21 Briefly, the following criteria were used: mild HCM was
defined as end-diastolic left ventricular free wall (LVFWd) or septal
(IVSd) thickness of 6.0 to 6.5 mm or both with a normal LA/Ao of
≤1.5; moderate HCM was defined as LVFWd or IVSd of 6.0 to
6.5 mm or both in conjunction with LA/Ao of 1.5 to 1.8 or LVFWd or
IVSd of 6.5 to 7.0 mm or both with normal or increased LA/Ao up to
1.8; severe HCM was defined as LVFWd or IVSd >6.0 mm or both in
conjunction with LA/Ao >1.8 or if LVFWd or IVSd thickness or both
were >7.0 mm. Cats with ATE were evaluated as a separate group.
2.2 | Examination
All cats received a clinical examination, echocardiography with contin-
uous ECG monitoring and diagnostic blood testing. An oscillometric
blood pressure measurement (VET HDO Monitor, S + B medVet
GmbH Babenhausen, Germany) was only performed on cats with left
ventricular or papillary muscle hypertrophy according to current rec-
ommendations.30 The average of 5 measurements was taken and con-
sidered to be normal if systolic pressure was ≤160 mmHg. Blood
testing consisted of serum urea and creatinine concentration in all
cats as well as serum thyroxin (T4) concentration in cats with left ven-
tricular or papillary muscle hypertrophy. Cats were excluded if they
had a serum T4 concentration >4.5 μg/dL. The remaining serum was
frozen and stored at −80C for a maximum of 20 months for later
evaluations of cTnI using the currently most sensitive assay (ADVIA
Centaur TnI-Ultra, Siemens Healthcare Diagnostics Inc., Erlangen,
Germany) by IDEXX laboratories (Ludwigsburg, Germany), which has
been proven to be applicable in cats.26 All echocardiographic examina-
tions were performed using an ultrasound unit (Vivid 7 Dimension,
General Electric Medical System, Waukesha, Wisconsin) equipped
with a 7.0 (3.5/6.9) MHz phased-array transducer by a board-certified
cardiologist or a resident directly supervised by a cardiologist.
During the echocardiographic examinations, the cats were gently
restrained without sedation in right and left lateral recumbency. Stan-
dard echocardiographic views were obtained.31 Measurements of left
ventricular dimensions were acquired from 2-dimensional right par-
asternal long or short axis views. The thickest region was used for left
ventricular wall measurements using a leading edge-to-leading edge
method. For all variables, a mean value was calculated from at least
3 measurements and used for further analysis. Left atrial size was
assessed by measuring LA/Ao from the right parasternal short axis
view using an inner edge-to-inner edge method. The papillary muscles
were evaluated subjectively.
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2.3 | Statistical analysis
Statistical analysis was performed using commercial statistical software
(SPSS 18, IBM Inc., New York and MedCal 11.5, Medcalc Software,
Ostend, Belgium). Statistical significance was defined as P < .05. All data
were analyzed descriptively and presented as median with interquartile
range (IQR). Mild outliners were defined as 1.5-3 times the IQR,
whereas marked outlines were defined as >3 times the IQR. Nonnormal
distribution of all data was confirmed by the Kolmogorov–Smirnov test.
Differences in the cTnI concentration among the different study groups
(healthy, equivocal, mild, moderate, severe [including a subgroup
analysis: compensated, decompensated, compensated under treat-
ment], ATE) were analyzed and compared among groups using a
Kruskal–Wallis test. Post hoc analysis was done according to Con-
over.32 Spearman's rank correlation was used to evaluate the effect
of age, sex, body weight, and total body surface area (BSA) on the
serum concentration of cTnI in the healthy control group. Correla-
tions among echocardiographic variables such as LVFWd, IVSd, left
ventricular internal diameter in diastole (LVIDd) and systole (LVIDs),
LA/Ao, and cTnI concentrations also were determined by Spearman's
rank correlation. Cutoffs were calculated using receiver-operating
characteristic (ROC) analysis and dot plots. Positive and negative
predictive values were calculated for each cutoff. Cats with ATE
were excluded from all correlation and ROC analyses because of
small sample size and extremely high median cTnI concentration.
3 | RESULTS
A total of 166 cats (male, 97; female, 69) of various breeds were
included. European Shorthair was the major breed represented
(n = 50), followed by Maine Coon (n = 40), British Shorthair (n = 35),
and Norwegian Forest cat (n = 25). Furthermore, there were 5 Per-
sian, 3 Siberian Forest Cats, and 8 cats belonging to other breeds. Of
the 166 evaluated cats, 87 were classified as being healthy and
60 had HCM of variable disease severity (mild, 16; moderate, 10;
severe, 34). Of the remaining 19 cats,15 cats were classified as
equivocal and 4 presented with ATE. A significant age difference
was found among study groups (P = .001) with healthy cats (median
age, 2.75 years; IQR, 1.5-5.92 years) being significantly younger than
cats with mild (median age, 9.92 years; IQR, 1.56-12.92 years), mod-
erate (median age, 11.46 years; IQR, 3.31-12.58 years), and severe
(median age, 6.38 years; IQR, 4.46-12.56 years) HCM. Female cats
were overrepresented in the healthy control group (60.9%) and ATE
group (25%), whereas male cats dominated in all other groups (equiv-
ocal, 73.3%; mild HCM, 68.7%; moderate HCM, 80.0%; severe HCM,
94.1%; P = .000001). No difference in weight was identified among
groups (P = .057). Additional clinical data are presented in Table 1.
3.1 | cTnI concentration
Twenty-four cats had a cTnI concentration below the laboratory's
detection limit of 0.006 ng/mL. Twenty-one of these cats belonged to
the healthy control group, 1 cat was classified as equivocal and 2 cats
had mild HCM. For statistical analysis, a cTnI concentration of
0.006 ng/mL was used for these cats.
The effects of age, sex, body weight, and BSA on the serum con-
centration of cTnI were evaluated in the group of healthy cats. Body
weight (P = .2, rs = −0.14), BSA (P = .24, rs = −0.13), and sex (P = .64,
rs = 0.05) did not have an effect on serum cTnl concentration. With
increasing age, a slight increase in cTnI concentration was observed,
but this difference was not significant (P = .42, rs = 0.09).
The median cTnI concentration was significantly different among
patient groups (P < .000001). Healthy cats and equivocal cats had sig-
nificantly lower median cTnI concentration compared to all other
groups. Furthermore, the median cTnI concentration was significantly
different between cats with mild HCM compared to those with severe
HCM. Cats with ATE had significantly higher median cTnI concentra-
tion compared to cats with mild or moderate HCM (Figure 1). The
lowest concentrations were found in healthy cats, at 0.013 ng/mL
(IQR, 0.006-0.025 ng/mL), whereas the highest cTnI concentrations
were found in cats with ATE with a median cTnI of 6.413 ng/mL (IQR,
4.336-11.266 ng/mL; Table 1).
To evaluate the effect of decompensation on cTnI concentra-
tion, a subgroup analysis was performed in the severe HCM group.
Thus, the severe HCM group was divided into compensated (n = 15),
decompensated (n = 11), and compensated under treatment (n = 8),
and the cTnI concentration compared among these 3 subgroups.
The cTnI concentration was significantly lower in the compensated
group (median, 0.31 ng/mL; IQR, 0.17-0.63 ng/mL) than in the
decompensated group (median, 4.11 ng/mL; IQR, 2.36-7.08 ng/mL)
and compensated under treatment group (median, 0.64 g/mL; IQR,
0.47-2.11 ng/mL; P = .00004; Figure 2).
3.2 | Correlation of echocardiographic variables
and cTnI
A strong and significant correlation was found between cTnI concen-
tration and LVFWd (P < .0001, rs = 0.69). The correlation between
cTnI concentration and IVSd and LA/Ao was mild, but significant
(P < .0001, rs = 0.43 and 0.52, respectively). A significant negative cor-
relation was found between cTnI concentration and LVIDd (P < .0001,
rs = −0.36) and LVIDs (P < .0001, rs = −0.43).
3.3 | Cutoffs
Healthy cats and cats with HCM were used for the calculation of a
cutoff. Equivocal cats initially were excluded from the analysis. How-
ever, a second analysis was performed in which equivocal cats first
were regarded as healthy and secondly as having HCM. Cats with
ATE were excluded from all ROC analyses. A cutoff of >0.06 ng/mL
differentiated healthy cats from cats with HCM with a sensitivity of
91.7% and specificity of 95.4% (AUC, 0.95; 95% CI, 0.899-0.978;
Figure 3) if equivocal cats were excluded from the analysis. By apply-
ing this cutoff, 3 cats were classified as false positive and 4 cats as
false negative, whereby the false negative cats all had mild HCM only
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(Figure 4). The optimal cutoff to differentiate healthy cats from cats
with asymptomatic HCM also was >0.06 ng/mL (sensitivity, 87.8%;
specificity, 95.4%; AUC, 0.93; 95% CI, 0.864-0.964). Regarding the
detection of asymptomatic cats with severe HCM, the cutoff of
>0.06 ng/mL had a sensitivity of 100% and specificity of 95.4% (AUC,
0.99; 95% CI, 0.947-1.0). Additional results are shown in Table 2.
Assuming a prevalence of 14.7%3 in the general population, the
positive and negative predictive values for cTnI to differentiate
healthy cats from cats with HCM were 77.4% and 98.5%, respec-
tively, whereas for asymptomatic cats with HCM, the values were
76.7% and 97.8%, respectively.
4 | DISCUSSION
To our knowledge, our study is the first to evaluate the usefulness of
a sensitive cTnI assay as a screening test for HCM in cats.
A screening test should be an easily applicable procedure that can
identify individuals from an apparently healthy population that are likely
to have a disease or defect.33 It is recommended that middle aged to
older cats receive laboratory assessments as part of their routine health
care.34 Therefore, cTnI, which can be analyzed in the blood as a marker
of myocardial injury,35 appears to be an ideal measurement. Earlier
studies have shown that first-generation cTnI test results are increased
in cats with HCM compared to healthy controls.18,19,26,36 Some
concerns have been raised that only cats with moderate-to-severe
HCM can be identified, thus rendering the assay less useful as a screen-
ing test. This statement however was related to first-generation cTnI
tests.27 In our study, we were able to show that median cTnI concen-
tration increased with increasing disease severity and that this differ-
ence already was significant between healthy cats and cats with mild
HCM. A significant difference also was found between asymptomatic
cats with severe HCM and those that were decompensated or compen-
sated under treatment. These findings are similar to those previously
reported in which a sensitive cTnI assay also was used.26 Only between
cats with moderate HCM compared to cats with mild or severe HCM
as well as between cats with severe HCM compared to cats with ATE
did this difference not reach significance. This observation might be a
consequence of the small sample size of the moderate HCM and ATE
groups. In agreement with a previous study,19 the highest cTnI concen-
trations were found in the ATE group. However, some decompensated
cats with severe HCM also had very high cTnI concentrations. Because
follow-up was not part of our study design and no histopathology was
done, myocarditis cannot be ruled out completely in these cats.
The determined cutoff of >0.06 ng/mL reliably differentiated
between healthy cats and cats with HCM (sensitivity, 91.7%; specific-
ity, 95.4%). This cutoff also showed good discrimination between
F IGURE 1 Serum cTnI concentration in healthy cats and cats with HCM of different disease severity as well as with arterial
thromboembolism. The middle line of each box stands for the median, whereas the upper line and lower line represent the 75th and 25th
percentiles, respectively. Mild outliners (1.5-3 times the IQR) are marked with a circle (), whereas marked outlines (>3 times the IQR) are marked
with an asterisk (*). The median cTnI concentration was significantly different among most patient groups (P < .000001)
#P < .05, if compared to the healthy control group. Post hoc analysis according to Conover.32
~P < .05, if compared to the mild HCM group. Post hoc analysis according to Conover.32
^P < .05, if compared to the moderate HCM group. Post hoc analysis according to Conover.32
cTnI, cardiac troponin I; IQR, interquartile range; HCM, hypertrophic cardiomyopathy; ATE, arterial thromboembolism
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healthy and asymptomatic cats with HCM (sensitivity, 87.8%;
specificity, 95.4%), but it should be kept in mind that the reported
sensitivities and specificities only apply for cats in which com-
orbidities have been excluded. Our determined cutoff is lower than
that previously reported.18,19,26 Similar to a previous study,26 we
used the currently most sensitive cTnI assay with a detection limit of
0.006 ng/mL, whereas the lowest detection limits in other previous
studies were 0.03 ng/ml19 and 0.2 ng/ml,18 respectively. Further-
more, a previous study19 used twice the SD above the mean as a
cutoff to detect moderate-to-severe HCM. Additionally, only 16% of
the healthy control cats in that study19 received an echocardio-
graphic examination, whereas the other cats were regarded as
healthy based on physical examination, potentially allowing a high
number of false negatives. The difference between our cutoff and
that determined in a previous study26 might be explained by the dif-
ferent grading system and exclusion criteria used in our study.
Because impaired renal function,35,37 hyperthyroidism,38 and hyper-
tension39 cause increases in cTnI, we excluded such cats from our
study. However, the previous study26 included cats with concomi-
tant chronic kidney disease and used higher blood pressure and
higher serum T4 concentration as exclusion criteria. Furthermore, in
our study cTnI was measured in serum, whereas the previous
study26 used heparinized plasma. A recent study performed in dogs
showed no statistically significant difference between mean cTnI
concentration in serum versus plasma in ethylenediamine tetra-ace-
tate.40 However, the same might not be true for heparinized plasma.
A significant difference was found between the cTnI concentra-
tion of the healthy control group compared to the equivocal group.
This might indicate that some of the equivocal cats already had myo-
cardial damage as a consequence of developing HCM. According to
the PawPeds screening criteria,27 some of these equivocal cats would
have been classified as mild HCM, whereas others still would be reg-
arded as healthy if the criteria of the ACVIM Registry of Cardiac
F IGURE 2 Serum cardiac troponin I concentration of cats with
severe HCM that were either compensated (n = 15), acutely
decompensated (n = 11), or compensated under treatment (n = 8).
The middle line of each box stands for the median, whereas the upper
line and lower line represent the 75th and 25th percentiles,
respectively. Mild outliners (1.5-3 times the IQR) are marked with a
circle (), whereas marked outlines (>3 times the IQR) are marked with
an asterisk (*). The median cTnI concentration was significantly lower
in the compensated group compared to the 2 other groups
#P < .05, if compared to the compensated severe HCM group. Post
hoc analysis according to Conover.32
HCM, hypertrophic cardiomyopathy; cTnI, cardiac troponin I
F IGURE 3 Receiver-operating characteristic (ROC) curve
displaying the sensitivity and specificity of serum cardiac troponin I
concentration (cTnI) distinguishing healthy cats from cats with
hypertrophic cardiomyopathy of different disease severity. The area
under the curve is 0.95
F IGURE 4 Dot plot with the black line demonstrating the cutoff
of 0.06 ng/mL. Dots above the line in the healthy control group
demonstrate the false positive, whereas dots below the line in cats
with HCM represent false negatives
cTnI, cardiac troponin I; HCM, hypertrophic cardiomyopathy
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Health were applied.27 Therefore, we excluded the equivocal group
from the initial ROC analysis. Because doing so could influence our
results, we performed a second analysis in which we regarded the
equivocal group as either being healthy or as having HCM. Either way,
this did not change the cutoff of >0.06 ng/mL, and both specificity
and AUC remained high. Sensitivity remained equally high (91.7%) if
the equivocal group was regarded as being healthy, but decreased to
76% if these cats were regarded as having HCM.
N-terminal pro-B type natriuretic peptide already has been evalu-
ated in terms of differentiating normal cats from cats only mildly
affected with HCM.21,22 However, the NT-proBNP assay is almost
twice as expensive as the cTnI assay in some countries. Furthermore,
NT-proBNP predominantly is secreted in response to myocardial stretch
as well as volume and pressure overload,41,42 whereas cTnI is a marker
of myocardial injury itself35 and thus might be more suitable in cats with
HCM. On the other hand, cTnI, like NT-proBNP,17 can be influenced by
various noncardiac diseases that sometimes cause greater increases in
the cTnI concentration than do primary cardiac diseases themselves.17,35
Therefore, further diagnostic evaluation is required if increased bio-
marker concentrations are identified. It would have been interesting to
determine, how both biomarkers would perform against each other, but
doing so was not part of our study design.
During our study, no follow-up was performed to evaluate the role
of cTnl as an early marker for cats at risk of later developing HCM.
Further research is needed regarding this matter. Assessing the role of
cTnl based on different definition criteria for HCM also could be of
interest, especially considering the results in the group defined as
equivocal in our study.
Conflicting results have been reported regarding the difference in
cTnI between asymptomatic cats with severe HCM and those with
CHF.18,19 We found a significant difference between the cTnI concen-
tration of asymptomatic cats and acutely decompensated cats with
severe HCM. Similar data are available for humans, where cTnI has
been shown to correlate with the severity of CHF and remains a prog-
nostic marker for adverse outcome and longer hospitalization.43–50
Whereas a previous study19 did not find a significant difference; in our
study, a significant difference was found between the cTnI concentra-
tion of cats with compensated severe HCM and those with compen-
sated disease under treatment. This finding could implicate ongoing
damage of the myocardium with disease progression despite clinical
stabilization under treatment and supports the findings of another
study,36 in which cTnI concentration at admission was prognostic for
survival. In humans with stable chronic heart failure, 1 study51 found
that higher baseline cTnI concentration and an increase over a 6-month
period were independent significant prognostic predictors of adverse
outcome.
Factors influencing cTnI concentration were evaluated in the
healthy control group. Similar to a previous report,26 no significant
difference in terms of sex could be found. The observed increase in
the proportion of male cats with increased disease severity is in
agreement with the current literature.3,14,15,52,53
In our study, age did not significantly influence cTnl concentration.
However, the median age of the healthy control group was only 4 years,
possibly underrepresenting older, healthy cats. Dogs and humans also
tend to have higher cTnI concentrations with increasing age.54–56
As described previously, the cTnI concentration correlated strongly
with LVFWd18,19,26,36 and mildly with IVSd.26 Additionally, we found a
mild positive correlation with LA/Ao as well as a significant negative
correlation with LVIDd and LVIDs. These findings partially can be
explained by the larger sample size of our study compared to some pre-
vious studies.18,19 Furthermore, a different severity categorization sys-
tem was used in our study, which included LA/Ao as an independent
variable.
Our study had several limitations. First, cTnI concentration was
only evaluated once in every cat. Therefore, no individual or circadian
changes in cTnI concentration could be taken into account. In healthy
dogs, a within-subject coefficient of variability of 48.1% has been
reported.57 Second, because follow-up echocardiography was not part
of the study design, some cats might have had transient myocardial
thickening instead of a classical HCM. However, transient myocardial
thickening in cats so far has only be reported in conjunction with
CHF.58,59 An influence on our determined cutoff therefore seems
unlikely. No histopathology was done to assess the extent of myocar-
dial damage and to rule out myocarditis. Thus, some cats in the con-
trol group could have had myocardial changes consistent with HCM
that were not yet evident on echocardiography. This would lead to a
falsely increased median cTnI concentration, decreasing the specificity
of the test. However, echocardiography still represents the current
antemortem gold standard for the diagnosis of HCM.27 Lastly, many
cats in the healthy control group consisted of animals being evaluated
for breeding, which explains the higher proportion of younger female
cats in that group. This design feature could have influenced our
results, because age might affect cTnI concentration. Furthermore,
older cats are more likely to have comorbidities, which potentially
TABLE 2 Results of the receiver-operating curve analyses to determine cutoffs for cTnI
Cutoff (ng/ml) Sensitivity Specificity Area under the curve 95% confidence interval
Healthy versus HCM 0.06 91.7% 95.4% 0.95 0.899-0.978
Healthy versus asymptomatic HCM 0.06 87.8% 95.4% 0.93 0.864-0.964
Healthy versus severe asymptomatic HCM 0.06 100% 95.4% 0.99 0.947-1.0
Healthy with equivocal versus HCM 0.06 91.7% 94.1% 0.95 0.899-0.975
Healthy versus equivocal with HCM 0.06 76% 95.4% 0.9 0.838-0.938
Cats with arterial thromboembolism were excluded from all analyses.
Abbreviations: cTnI, cardiac troponin I; HCM, hypertrophic cardiomyopathy.
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could affect cTnI concentration as well. Finally, we did not evaluate
the effect of comorbidities on our test results. Various cardiac and
noncardiac diseases can influence cTnI concentration.35 However, the
presence of unknown comorbidities in an apparently healthy popula-
tion of cats is a general limitation for the use of biomarkers as a
screening test.
Our study showed that a cutoff of >0.06 ng/mL for cTnI can be
used as a screening test for HCM in otherwise healthy cats. With a
negative predictive value of 97.8% for asymptomatic cats only 2% of
affected cats would have been missed. On the other hand, because of
the positive predictive value of 76.7% almost 25% of the positive cats
in an otherwise healthy screening population would be false positive,
even if all other causes for increased cTnI concentration had been
excluded. This observation highlights the need for subsequent echo-
cardiography to confirm the diagnosis if increased cTnI concentration
is detected in an otherwise healthy cat.
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